These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30504717)

  • 1. Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors.
    Hurtado M; Sankpal UT; Kaba A; Mahammad S; Chhabra J; Brown DT; Gurung RK; Holder AA; Vishwanatha JK; Basha R
    Cell Physiol Biochem; 2018; 51(4):1894-1907. PubMed ID: 30504717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study.
    Eslin D; Lee C; Sankpal UT; Maliakal P; Sutphin RM; Abraham L; Basha R
    Tumour Biol; 2013 Oct; 34(5):2781-9. PubMed ID: 23686785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF-kB translocation to nucleus and cell cycle phase distribution.
    Basha R; Connelly SF; Sankpal UT; Nagaraju GP; Patel H; Vishwanatha JK; Shelake S; Tabor-Simecka L; Shoji M; Simecka JW; El-Rayes B
    J Nutr Biochem; 2016 May; 31():77-87. PubMed ID: 27133426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
    Sankpal UT; Ingersoll SB; Ahmad S; Holloway RW; Bhat VB; Simecka JW; Daniel L; Kariali E; Vishwanatha JK; Basha R
    Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth.
    Shelake S; Sankpal UT; Paul Bowman W; Wise M; Ray A; Basha R
    Invest New Drugs; 2017 Apr; 35(2):158-165. PubMed ID: 28025760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
    Abdelrahim M; Baker CH; Abbruzzese JL; Safe S
    J Natl Cancer Inst; 2006 Jun; 98(12):855-68. PubMed ID: 16788159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma.
    Eslin D; Sankpal UT; Lee C; Sutphin RM; Maliakal P; Currier E; Sholler G; Khan M; Basha R
    Mol Carcinog; 2013 May; 52(5):377-86. PubMed ID: 22213339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.
    Sankpal UT; Abdelrahim M; Connelly SF; Lee CM; Madero-Visbal R; Colon J; Smith J; Safe S; Maliakal P; Basha R
    Prostate; 2012 Nov; 72(15):1648-58. PubMed ID: 22473873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells.
    Sankpal UT; Goodison S; Jones-Pauley M; Hurtado M; Zhang F; Basha R
    Oncotarget; 2017 Feb; 8(9):14593-14603. PubMed ID: 28099934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolfenamic acid inhibits colon cancer cell and tumor growth and induces degradation of specificity protein (Sp) transcription factors.
    Pathi S; Li X; Safe S
    Mol Carcinog; 2014 Feb; 53 Suppl 1():E53-61. PubMed ID: 23670891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression.
    Konduri S; Colon J; Baker CH; Safe S; Abbruzzese JL; Abudayyeh A; Basha MR; Abdelrahim M
    Mol Cancer Ther; 2009 Mar; 8(3):533-42. PubMed ID: 19258429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid: a pre-clinical evaluation.
    Sankpal UT; Lee CM; Connelly SF; Kayaleh O; Eslin D; Sutphin R; Goodison S; Adwan L; Zawia NH; Lichtenberger LM; Basha R
    Cell Physiol Biochem; 2013; 32(3):675-86. PubMed ID: 24030139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation.
    Jutooru I; Chadalapaka G; Lei P; Safe S
    J Biol Chem; 2010 Aug; 285(33):25332-44. PubMed ID: 20538607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copper-tolfenamic acid: evaluation of stability and anti-cancer activity.
    Hurtado M; Sankpal UT; Chhabra J; Brown DT; Maram R; Patel R; Gurung RK; Simecka J; Holder AA; Basha R
    Invest New Drugs; 2019 Feb; 37(1):27-34. PubMed ID: 29761244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of tolfenamic acid and curcumin induces colon cancer cell growth inhibition through modulating specific transcription factors and reactive oxygen species.
    Sankpal UT; Nagaraju GP; Gottipolu SR; Hurtado M; Jordan CG; Simecka JW; Shoji M; El-Rayes B; Basha R
    Oncotarget; 2016 Jan; 7(3):3186-200. PubMed ID: 26672603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 are non-oncogene addiction genes in cancer cells.
    Hedrick E; Cheng Y; Jin UH; Kim K; Safe S
    Oncotarget; 2016 Apr; 7(16):22245-56. PubMed ID: 26967243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met.
    Papineni S; Chintharlapalli S; Abdelrahim M; Lee SO; Burghardt R; Abudayyeh A; Baker C; Herrera L; Safe S
    Carcinogenesis; 2009 Jul; 30(7):1193-201. PubMed ID: 19406933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice.
    Colon J; Basha MR; Madero-Visbal R; Konduri S; Baker CH; Herrera LJ; Safe S; Sheikh-Hamad D; Abudayyeh A; Alvarado B; Abdelrahim M
    Invest New Drugs; 2011 Feb; 29(1):41-51. PubMed ID: 19851711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.
    Jia Z; Gao Y; Wang L; Li Q; Zhang J; Le X; Wei D; Yao JC; Chang DZ; Huang S; Xie K
    Cancer Res; 2010 Feb; 70(3):1111-9. PubMed ID: 20086170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-leukemic response of a NSAID, tolfenamic acid.
    Sutphin RM; Connelly SF; Lee CM; Sankpal UT; Eslin D; Khan M; Pius H; Basha R
    Target Oncol; 2014 Jun; 9(2):135-44. PubMed ID: 23609055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.